Previous 10 | Next 10 |
WESTMINSTER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that James Flynn has joined its Board of Directors. “We are pleased to welcome James Flynn to our Board,” said Robert E. Conway, Chairman of ARCA’s Board of Dir...
ARCA biopharma press release ( NASDAQ: ABIO ): Q3 GAAP EPS of -$0.16. Cash and cash equivalents were $43.9 million as of September 30, 2022, compared to $53.4 million as of December 31, 2021. ARCA believes that its current cash and cash equivalents, will be suffic...
WESTMINSTER, Colo., Oct. 28, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2022 financial results and...
ARCA biopharma press release ( NASDAQ: ABIO ): Q2 GAAP EPS of -$0.22. Cash and cash equivalents of $46.44M. Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “We are in the process of evaluating options for creating stockh...
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company ...
WESTMINSTER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors. “We are pleased to welcome Jacob Ma-Weaver, the managing member of ARCA’s largest shareholder, to our Board...
WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor. In April 2022, the Board of Directors established a Special Committee to explore and eva...
Activist is pushing ARCA biopharma to stop new developments and return cash to shareholders. Subsequently, management has started a strategic review. The company's cash position (minus liabilities) stands at $3.19/share offering a potential 45% upside if things play out according ...
ARCA biopharma press release (NASDAQ:ABIO): Q1 GAAP EPS of -$0.23. Cash and cash equivalents were $49.1 million as of March 31, 2022, compared to $53.4 million as of December 31, 2021. ARCA believes that its current cash and cash equivalents, will be sufficient to fund its operations at the c...
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company a...
News, Short Squeeze, Breakout and More Instantly...
Bank of the James Financial Group Inc. (BOTJ) is expected to report for Q2 2024 Electrolux AB ADR (ELUXY) is expected to report $-0.18 for Q2 2024 Coca Cola Femsa S.A.B. de C.V. American Depositary Shares each representing 10 Units (each Unit consists of 3 Series B Shares and 5 Series L S...
NEW YORK, NY / ACCESSWIRE / May 22, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Squarespace, Inc. (NYSE:SQSP)'s sale...